» Articles » PMID: 34085841

Metalloproteinases and Their Inhibitors Are Associated with Pulmonary Arterial Stiffness and Ventricular Function in Pediatric Pulmonary Hypertension

Abstract

Disturbed balance between matrix metalloproteinases (MMPs) and their respective tissue inhibitors (TIMPs) is a well-recognized pathophysiological component of pulmonary arterial hypertension (PAH). Both classes of proteinases have been associated with clinical outcomes as well as with specific pathological features of ventricular dysfunction and pulmonary arterial remodeling. The purpose of this study was to evaluate the circulating levels of MMPs and TIMPs in children with PAH undergoing the same-day cardiac magnetic resonance imaging (MRI) and right heart catheterization. Children with PAH ( = 21) underwent a same-day catheterization, comprehensive cardiac MRI evaluation, and blood sample collection for proteomic analysis. Correlative analysis was performed between protein levels and ) standard PAH indices from catheterization, ) cardiac MRI hemodynamics, and ) pulmonary arterial stiffness. MMP-8 was significantly associated with the right ventricular end-diastolic volume ( = 0.45, = 0.04). MMP-9 levels were significantly associated with stroke volume ( = -0.49, = 0.03) and pulmonary vascular resistance ( = 0.49, = 0.03). MMP-9 was further associated with main pulmonary arterial stiffness evaluated by relative area change ( = -0.79, < 0.01).TIMP-2 and TIMP-4 levels were further associated with the right pulmonary artery pulse wave velocity ( = 0.51, = 0.03) and backward compression wave ( = 0.52, = 0.02), respectively. MMPs and TIMPs warrant further clinically prognostic evaluation in conjunction with the conventional cardiac MRI hemodynamic indices. Metalloproteinases have been associated with clinical outcomes in pulmonary hypertension and with specific pathological features of ventricular dysfunction and pulmonary arterial remodeling. In this study, we demonstrated that plasma circulating levels of metalloproteinases and their inhibitors are associated with standard cardiac MRI hemodynamic indices and with the markers of proximal pulmonary arterial stiffness. Particularly, MMP-9 and TIMP-2 were associated with several different markers of pulmonary arterial stiffness. These findings suggest the interplay between the extracellular matrix (ECM) remodeling and overall hemodynamic status in children with PAH might be assessed using the peripheral circulating MMP and TIMP levels.

Citing Articles

Utility of Serum Matrix Metalloproteinase-7 as a Biomarker in Cholestatic Infants with Congenital Heart Disease.

Pandurangi S, Kim M, Noriega N, Conant B, Seo J, Mourya R Pediatr Cardiol. 2024; .

PMID: 39499285 DOI: 10.1007/s00246-024-03696-2.


Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry.

Amubieya O, Todd J, Neely M, Kaner R, Lasky J, Namen A PLoS One. 2024; 19(10):e0312044.

PMID: 39418259 PMC: 11486396. DOI: 10.1371/journal.pone.0312044.


The TIMP protein family: diverse roles in pathophysiology.

Coates-Park S, Rich J, Stetler-Stevenson W, Peeney D Am J Physiol Cell Physiol. 2024; 326(3):C917-C934.

PMID: 38284123 PMC: 11193487. DOI: 10.1152/ajpcell.00699.2023.


Phenomic Imaging.

Lan L, Feng K, Wu Y, Zhang W, Wei L, Che H Phenomics. 2024; 3(6):597-612.

PMID: 38223684 PMC: 10781914. DOI: 10.1007/s43657-023-00128-8.


Circulating biomarkers of extracellular matrix dysregulation are associated with adverse post-stage 2 outcomes in infants with single ventricle heart disease.

Frank B, Nandy D, Khailova L, Mitchell M, Morgan G, Twite M Sci Rep. 2023; 13(1):16318.

PMID: 37770592 PMC: 10539532. DOI: 10.1038/s41598-023-43562-4.


References
1.
Hunter K, Lee P, Lanning C, Ivy D, Kirby K, Claussen L . Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J. 2007; 155(1):166-74. PMC: 3139982. DOI: 10.1016/j.ahj.2007.08.014. View

2.
Swift A, Rajaram S, Capener D, Elliot C, Condliffe R, Wild J . LGE patterns in pulmonary hypertension do not impact overall mortality. JACC Cardiovasc Imaging. 2014; 7(12):1209-17. DOI: 10.1016/j.jcmg.2014.08.014. View

3.
Del Cerro M, Moledina S, Haworth S, Ivy D, Al Dabbagh M, Banjar H . Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. Pulm Circ. 2016; 6(1):118-25. PMC: 4809667. DOI: 10.1086/685102. View

4.
Ivy D, Abman S, Barst R, Berger R, Bonnet D, Fleming T . Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D117-26. DOI: 10.1016/j.jacc.2013.10.028. View

5.
Parker K, Jones C . Forward and backward running waves in the arteries: analysis using the method of characteristics. J Biomech Eng. 1990; 112(3):322-6. DOI: 10.1115/1.2891191. View